CAPRELSA (vandetanib) is a prescription medication used in the treatment of certain types of thyroid cancer. Specifically, it is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease. CAPRELSA works as a kinase inhibitor, targeting multiple tyrosine kinases, including RET, VEGFR, and EGFR, which are involved in the pathogenesis of thyroid cancer and tumor growth. By inhibiting these kinases, CAPRELSA can slow the growth of cancer cells and reduce the spread of the disease. It is available in tablet form and is taken orally. Like all medications, CAPRELSA can cause side effects and is not suitable for everyone; thus, it should be used under the supervision of a healthcare provider experienced in the treatment of thyroid cancer.